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World wide the United States has the third largest elderly population (people
over age 65) and the largest old-old population (people age 80 and above). In 1987,
one in eight Americans, or approximately 30 million people, were at least 65 years
of age. By the year 2030 the number of persons aged 65 and above is expected to
double to an estimated 23 percent of the total population (1). Due to the projected
increase in life span, increasing attention is being given to research relating to the
aging process, medical complications associated with aging, and to the nutritional
status of older adults (2-4).
Although not inevitable, health status often declines with advancing age.
Older adults have a high incidence of chronic diseases, medication use, and
sedentary lifestyles (5). Poor dietary intake among the elderly may contribute to
declining health status and increased risk of diet-related diseases such as coronary
heart disease, glucose intolerance, and maturity-onset diabetes (5-7).
The elderly, as a group, are at increased risk of poor nutritional status due to
several factors including socioeconomic pressures, depression, reduced mobility,
loneliness, aging body tissues, physical and mental disabilities, and food and drug
interactions (3,8,9). Nutrition intervention to improve dietary adequacy could
possibly divert or slow the progression of many disease conditions that occur with
aging (5).
Diabetes is of particular concern among older adults. Diabetes is one of the
six leading causes of death after age 65 (1). Approximately 20-30 percent of
individuals aged 65 or older have impaired glucose tolerance, as indicated by
elevated fasting glucose concentrations, while 10-35 percent have actual diabetes
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(10). Increased postprandial plasma glucose concentrations have been reported with
age (11,12). In addition, decreased glucose tolerance has been reported with
increased age (12,13). This is of concern because impaired glucose tolerance is a
leading indicator of non-insulin dependent diabetes (14). One hypothesis for the
observed decrease in glucose tolerance among older adults is that insulin is less
biologically active with age (15). Inadequate dietary zinc and chromium intake also
may be associated with the observed increase in glucose intolerance among older
adults (5,7,14,16).
The micronutrients zinc and chromium both have roles in insulin action and
glucose homeostasis (14,17). Zinc is involved in many enzyme systems involved in
both the activation and inhibition of glucose metabolism (18). Zinc also has a role
in insulin biosynthesis, storage and release from pancreatic beta cells, and is
involved in insulin configurational changes which enhance its binding to receptors
(18,19). Chromium also has a major role in maintaining normal glucose metabolism
and in potentiating insulin response (14,20). Chromium is an integral part of the
glucose tolerance factor, or dinicotinic acid glutathione complex (21).
The role of chromium and zinc with insulin, glucose tolerance and diabetes is
a particular concern among older adults due to reported poor dietary intakes of these
trace minerals among the elderly. Although there is minimal evidence of zinc
deficiency among adults in the United States, several studies have indicated that
many elderly have zinc intakes below the Recommended Dietary Allowance (RDA)
for zinc of 15 and 12 mg per day for men and women aged 51 and above,
respectively (3,22-24). Sandstead et ale (23) reported zinc intakes among the elderly
to be approximately 10.5 mg and 7.6 mg per day for men and women, respectively,
using the Nationwide Food Consumption Survey data. In addition, several studies
have also reported that average dietary chromium intakes among the elderly are
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below the adults estimated safe and adequate daily dietary intake (ESADDI) of 50 to
200 micrograms per day (6,20,25). Bunker et al. (20) reported average chromium
intakes among the elderly of 25 ug/day.
As a result of the increased incidence of diabetes among the elderly, the roles
of zinc and chromium with glucose and insulin metabolism, and the reported low
dietary intake of these micronutrients among older adults, the effect of zinc or
chromium supplementation on plasma glucose and serum insulin in adults age 50 and
above needs further investigation.
Objective
The objective of this research project was to evaluate the effects of zinc or
chromium supplementation on plasma glucose and serum insulin concentrations in
adults age 50 and older.
Null Hypotheses
Ho 1: There will be no significant relationship between initial dietary intake
and plasma glucose or serum insulin concentrations in adults age 50 and older.
Ho 2: There will be no significant effect due to eight weeks zinc
supplementation on mean plasma glucose concentration in adults age 50 and older.
Ho 3: There will be no significant effect due to eight weeks zinc
supplementation on mean serum insulin concentration in adults age 50 and older.
Ho 4: There will be no significant effect due to eight weeks chromium
supplementation on mean plasma glucose concentration in adults age 50 and older.
Ho 5: There will be no significant effect due to eight weeks chromium
supplementation on mean serum insulin concentration in adults age 50 and older.
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Assumptions
It was assumed that the subjects:
1. were healthy for their age group.
2. were not diabetic.
3. took the supplement as directed (one capsule each morning and evening with
meals).
4. did not change their exercise or eating habits during the course of the study.
5. correctly recorded their three day food intakes before each data collection period.
6. fasted twelve hours before each data collection period.
7. maintained their weight throughout the course of the study.
Limitations
Limitations of the study included:
1. Subjects participating in the study were volunteers.
2. Subjects were on self-selected diets.
3. Subjects food records were self-reported.
4. The sample size was small, less than 10 subjects per treatment group.
5. Subjects received supplementation for only eight weeks.
6. The majority of the subjects had normal fasting plasma glucose and serum insulin
concentrations.
Definitions of Terms
ELDERLY ADULTS: Those persons age 65 and older (1).
OLDER ADULTS: Those persons age 50 and older.
4
Thesis Format





Due to the increased incidence of diabetes and glucose intolerance with age,
and the role of zinc and chromium with glucose tolerance and insulin action.
Understanding trace minerals and their importance in the elderly, this chapter
contains a review of the literature on zinc and chromium, their roles with glucose
and insulin, and how these may affect the elderly.
ZINC
Food Sources
The recommended dietary allowance for zinc is 15 mg and 12 mg per day for
adult men and women respectively (26). Meats and dairy products are the major
dietary sources of zinc in typical American diets. Estimates indicate that 43 % of
dietary zinc is provided by meat, poultry and fish, and 25 % is provided from milk,
ice cream, eggs and cheese (23). Whole grain breads, nuts, wheat germ and
shellfish are rich sources of zinc whereas white fish and vegetables are poor sources
(27).
Zinc bioavailability from foods ranges between 14% and 41 % (28). Animal
products such as eggs, meat, seafood, and liver provide highly available zinc,
whereas zinc from plant products such as whole grains is less available (23,28,29).
Compounds in food, such as ferrous iron, phytates and phosphorus, can adversely
affect zinc absorption (23,30,31,32). Lonnerdal et ale (33) reported low zinc
absorption from soy formulas with high phytate content. In addition to compounds
in food affecting zinc absorption, an individuals' need also can affect zinc
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absorption. Increased need for zinc has been observed to result in increase zinc
absorption (34).
The zinc body pool in a nonnal 70 kg adult is about 1.5 to 2.0 grams.
Plasma zinc is present primarily bound to albumin, but can also bind to other
proteins, such as transferrin and ceruloplasmin (34). Zinc is present in all body
tissues, fluids, and secretions, but is chiefly found in skeletal muscle and bone (34).
Zinc is an essential trace mineral which has many important roles in the body
(35,36). Zinc functions to preserve enzyme integrity, and is involved with more
than 80 metalloenzymes and proteins, including the synthesis of deoxyribonucleic
acid (DNA) and ribonucleic acid (RNA) (35,36,37). Zinc is necessary for growth,
cell division, reproduction, wound healing, taste acuity, and normal immune
function (23). Zinc also is directly involved in insulin metabolism (38).
Common signs of zinc deficiency include cell mediated immunological
abnormalities, loss of appetite, decreased taste acuity, retarded growth and skin
changes (23). Decreased insulin response and impaired glucose tolerance have also
been observed with zinc deficiency (28). Zinc deficiency can have a significant
effect on serum albumin, transferrin and prealbumin concentrations. Seven patients
with various underlying diseases became zinc deficient on TPN solutions that
contained only 0.5 mg/L of zinc. Compared to healthy controls, all patients had
decreased mean serum concentrations, of 22 ug/dl for zinc, 3.2 gldl for albumin,
211 g/dl for transferrin, and 14.5 mgtdl for prealbumin. All concentrations
increased after supplementation with 220 mg zinc sulfate (50 mg of elemental zinc)
up to three times daily or 3 to 12 mg zinc sulfate intravenously. All other
nutritional support remained the same. The authors did not report duration or
amount of zinc supplementation for each patient, but stated that serum zinc and
prealbumin increased rapidly after zinc supplementation. After zinc
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supplementation, improvements in skin lesions were observed among these subjects.
Diarrhea and impaired immune function, problems associated with poor zinc status,
also improved upon supplementation (39).
Zinc is considered to have a low toxicity threshold (40). Moderately
elevated zinc intakes are not easily detected; however, zinc toxicity has been
observed after ingestion of 2 or more grams of zinc as zinc sulfate. Symptoms of
zinc toxicity include nausea, vomiting, abdominal cramps, and gastrointestinal
irritation (41). Increased zinc intakes also have been shown to adversely affect
copper status (42).
Zinc Effect on Glucose Tolerance and Insulin
Insulin is stored in the beta cells of the pancreas as zinc crystals (8,43). Zinc
is involved in synthesis, storage, and release of insulin from pancreatic beta cells
(19,44). Incorporation of zinc into insulin induces conformational changes which
aids insulin in binding to receptors (43). In addition, zinc enhances cell uptake of
insulin (45,46).
It is postulated that decreased zinc status may correlate with decreased
glucose metabolism (18,47). Huber et al. (48) observed significant decreases in
insulin concentrations among zinc deficient rats compared with pair fed controls.
Zinc deficient rats demonstrated impaired glucose tolerance when a glucose
challenge was administered at higher infusion rates versus lower rates, indicating
peripheral insulin resistance (18). Hendricks and Mahoney (49) also observed
impaired glucose tolerance among zinc deficient rats when glucose was administered
intraperitoneally, although glucose intolerance was not evident when glucose was
administered orally. This impaired glucose tolerance developed slowly with low
zinc diets, and was corrected within one week with zinc supplementation. The
8
authors speculated that zinc deficiency impaired the release of insulin from the
pancreas, which results in elevated glucose concentrations. It also has been
proposed that decreased pancreatic insulin release observed with zinc deficiency may
lead to increased insulin resistance (9, 40). However, in a study by Quarterman and
Florence (50), no effects on glucose tolerance and plasma insulin were observed
among zinc deficient rats.
One hypothesis is that zinc may stimulate glucose metabolism by some
mechanism not yet identified that mimics the biological effects of insulin. Shisheva
et ale (45) observed that oral zinc supplementation lowered plasma glucose
concentration among diabetes-induced rats. Zinc stimulated glucose use in muscle
tissue, which in tum lowered glucose concentrations in the entire animal. The
researchers postulated that zinc is involved in mechanisms which stimulate hexose
transport, and also that zinc may enhance the oxidation of glucose to carbon dioxide
by glycolysis and by the pentose phoshate pathway. These researchers concluded
that oral zinc supplementation results in the ability of tissues to metabolize glucose,
although normal concentrations cannot be reached by a single treatment. Circulating
zinc is often lower among diabetics, therefore, this information may also be useful
in evaluating zinc homeostasis among humans and its' relationship to IDDM or
NIDDM.
Diabetes itself may have an effect on zinc absorption (18). Car et ale (47)
observed significantly decreased serum zinc concentrations among 30 IDDM and
NIDDM subjects, mean age 46, compared to 15 controls of similar age. However,
Kinlaw et ale (38) studied zinc metabolism in 20 controlled NIDDM patients, 25%
of whom had hyperzincuria. Using fasting blood samples before insulin
administration, it was determined that serum zinc concentrations did not differ
between diabetic subjects and non-diabetic controls. However, zinc loss via urine
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was greater when proteinuria was also present, which is explained by the fact that
zinc is protein bound. In this study, urinary zinc excretion was correlated positively
with serum glucose concentrations. Also, serum zinc did not correlate with
glycosylated hemoglobin concentrations among these subjects. In addition,
Honnorat et ale (45) studied 53 diabetic subjects including 18 with IDDM and 35
with NIDDM. Of the NIDDM subjects, 22 were treated with oral antidiabetic
agents and 13 were treated with insulin. All of the subjects demonstrated normal
mean plasma zinc concentrations of 15.3 umol/L. However, urinary zinc
concentrations were increased in IDDM and NIDDM subjects being treated with
insulin, with concentrations of approximately 16.2 umol/24 hours, whereas NIDDM
subjects not being treated with insulin had normal urinary zinc values of 11.3
umol/24 hours. These data indicate that urinary losses of zinc were not related to
decreases in plasma zinc or altered zinc status. Explanations for nonnal plasma zinc
in the presence of hyperglycemia may be that the quantity of zinc is insufficient in
long-acting insulin or that absorption of zinc may be enhanced in diabetic subjects.
There also may be decreased intestinal excretion of zinc and increased tissue
catabolism, although no relationship was observed between plasma or urinary zinc
and Body Mass Index (BMI) or age among any subjects. The authors reported that
hyperzincuria was not related to glycosylated hemoglobin concentrations.
Hyperinsulinemia is not usual among IDDM subjects which may explain the




The estimated safe and adequate daily dietary intake for chromium
(ESADDI) in adults is 50 to 200 ug per day (26). Foods rich in chromium include
turkey-ham, liver, whole grain products, brewer's yeast, raisins, black pepper,
prunes, coffee, tea, beer, and wine (51,52). Dairy products are generally poor
sources of chromium. Some types of food processing can increase the chromium
content of foods through use of stainless steel equipment (51). Anderson et ale (52)
found higher contents of chromium in packaged or prepared foods such as English
muffins, waffles and bagels. However, milling has been observed to decrease
chromium content of grain products. To date, accurate and complete data on
chromium content of foods are limited (51).
Intestinal absorption of inorganic chromium is relatively low in humans.
However, chromium absorption from the biologically active organic complex (GTF)
is high (51). It has been reported that chromium from food sources and chromium
chloride (CrCI3) supplements have similar absorption rates (53). Dietary chromium
intake level can also affect chromium absorption. Anderson and Kozlovsky (6)
reported that chromium absorption was inversely related to dietary intake in a study
including 10 males and 22 females, aged 25 to 65. Approximately 2% of dietary
chromium is absorbed at intakes of 10 ug/day and 0.5 % at chromium intakes of 40
ug/day.
The chromium body pool is approximately 1.7 mg (54). However, reliable
methods for evaluating clinical chromium status are not available to date (16,55).
Blood plasma, serum, urine and hair do not adequately reflect chromium status.
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Currently, relative chromium status is commonly evaluated using effects of
chromium supplementation on glucose tolerance (25,56).
Chromium is an essential trace element which functions to maintain normal
glucose metabolism and facilitate insulin function (7,14,16,20). Trivalent chromium
is an integral part of the glucose tolerance factor (GTF), or dinicotinic acid
glutathione complex. The exact structure of GTF, first identified in brewer's yeast,
has not been determined (21,57). Glucose tolerance factor is not considered a trace
element or vitamin, instead the biologically active chromium complex is believed to
resemble a hormone which is released in the blood in response to a stimulus, such as
insulin. Chromium potentiates the movement of glucose into the tissues, increases
insulin activity and therefore, can reduce the amount of insulin necessary to control
blood sugar (14,16). Chromium is also believed to have a role in nucleic acid and
lipid metabolism (6,21).
Impaired glucose tolerance has been observed with chromium deficiency
(14,16,20,58,59). In patients receiving total parenteral nutrition (TPN) solutions
containing no chromium, chromium supplementation resulted in greatly improved
insulin status and glucose tolerance (58,60,61). In one case, chromium deficiency
resulted after 5 months on TPN. The chromium content, if any, in the TPN solution
was not provided by the author, however, daily supplementation with 150 ug of
chromium resulted in improved glucose tolerance, decreased insulin requirement,
weight gain and cessation of encephalopathy (60).
Due to low absorption of trivalent chromium, toxicity from dietary intake is
rare (62). In one animal study, no toxicity was observed in rats consuming 5
mg/liter in water or 100 mg/kg in the diet throughout their lifetimes (63). Trivalent
chromium does not appear to be carcinogenic. However, increased bronchial cancer
incidence has been associated with occupational exposure among industrial workers
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to hexavalent fonus of chromium, which may be inhaled or absorbed through the
skin. To prevent workers from the risks of excess contact and exposure to
chromium compounds, the United States observes an atmospheric limit or a
threshold limit value-ceiling (TLV-C), which should never be exceeded (64).
Chromium Effect on Glucose Tolerance and Insulin
Lowered dietary chromium intake may be a factor in the development of age
related decreases in glucose tolerance and insulin response (7,65). However, current
studies are inconclusive as to the effects of chromium supplementation on glucose
tolerance, blood glucose concentrations, and insulin sensitivity among the elderly.
Lui et al. (59) observed a 50% improvement in glucose tolerance among
older women, aged 40 to 75 years after three months daily supplementation with 4
ug of chromium in 5 g of brewer's yeast. In addition, decreased insulin release,
indicating beneficial glucose control, was noted among both older and younger
subjects following chromium supplementation.
Anderson et ale (7) also reported a beneficial effect of chromium
supplementation among hyperglycemic subjects consuming controlled diets which
contained inadequate dietary chromium, less than 20 ug per day. In these subjects,
o to 90 minute glucose and insulin concentrations and glucagon were elevated on the
controlled inadequate chromium diets. After supplementation with 200 ug CrCl3 for
five weeks glucose, insulin and glucagon concentrations decreased in these subjects.
The authors suggested that these results could indicate that chromium may have an
effect on glucose and insulin concentrations by increasing glucagon sensitivity.
In addition, a beneficial effect was observed by Offenbaucher and Pi-Sunyer
(16), in a study including both nondiabetic and NIDDM subjects, mean age 78,
supplemented daily for eight weeks with 9 grams of chromium-rich brewer's yeast
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(experimental) or chromium-poor torula yeast (control). Improved glucose tolerance
and insulin sensitivity were observed in the chromium supplemented groups
compared to the control. Improvements in glucose tolerance and insulin sensitivity
also were observed even when diabetic subjects were omitted from the analysis;
these subjects were omitted in secondary analysis because they displayed better
initial glucose tolerance than non-diabetic subjects.
However, Riales et al. (65) observed inconclusive results among 23 men,
aged 31 to 60, supplemented with 200 ug/day of chromium chloride 5 days/week for
12 weeks. In this study, an improvement in glucose tolerance was observed at six
weeks, but not at 12 weeks, among 8 subjects in the supplemented group (n= 12)
and among 6 subjects in the placebo group (n=11). The author stated that the
observed decrease in glucose tolerance among both groups at 6, but not 12 weeks
supplementation may be due to noncompliance at 12 weeks or an unconscious
change in lifestyle. However, the authors did observe a trend towards decreased
insulin concentrations in the chromium supplemented group after 12 weeks
supplementation, possibly indicating increased insulin sensitivity.
No significant effect was observed by Uusitupa et ale (66) in fasting glucose
tolerance or serum insulin concentrations after 6 weeks supplementation with 200 ug
chromium cWoride compared to a placebo among 6 male (mean age 58 years, range
37 to 65) and 4 female (mean age 63 years, range 59 to 68) NIDDM subjects.
In addition, no effect due to chromium supplementation was observed in
fasting oral glucose or insulin concentrations in a study by Offenbacher et ale (67)
including 23 healthy elderly adults, 19 females and 4 males with an age range from
63 to 86 years, supplemented with 5 ug chromium as brewer's yeast, 200 ug
chromium cWoride or a lactose placebo for 10 weeks. The researchers reported no
significant effects in fasting oral glucose or insulin concentrations.
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ELDERLY
Increased Incidence of Diabetes with Age
Although not inevitable, health status often declines with advancing age.
Older adults have a high incidence of chronic disease, medication use and sedentary
lifestyle (5). Poor dietary intake among the elderly may contribute to declining
health status and increased risk of diet-related diseases such as obesity, coronary
heart disease, glucose intolerance, and maturity-onset diabetes (5-7,68).
Diabetes is of particular concern among older adults. Diabetes is one of the
six leading causes of death after age 65 (1). Approximately 20 to 30 percent of
individuals aged 65 or older have impaired glucose tolerance, as indicated by
elevated fasting glucose concentrations, while 10 to 35 percent have actual diabetes
(10). Increased postprandial plasma glucose concentrations have been reported with
age (11,12). Morley et ale (11) has reported increased postprandial plasma glucose
of approximately 5 to 10 mg/dl per decade after age 50, while fasting glucose
concentrations increased only 1 to 2 mg/dl per decade after age 50 (13). In
addition, decreased glucose tolerance has been reported with increased age (12,13).
This is of concern because impaired glucose tolerance is a leading indicator of non-
insulin dependent diabetes (14). Hypotheses for the observed decrease in glucose
tolerance among older adults include: decreased biologically active insulin, less
responsive pancreatic function, or decreased insulin sensitivity resulting from altered
pancreatic beta cell function (15,69). Increased glucose intolerance among older
adults also may be associated with inadequate dietary zinc and chromium intake
(5,7,14,16).
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Dietary Intake Among the Elderly
Specific nutrient needs for the elderly have not been evaluated extensively.
The RDA's for adults age 51 years and over are extrapolated from guidelines based
on younger, healthy individuals (26). Therefore, it is difficult to determine whether
reported intakes of older adults are adequate to maintain health (70). There may be
an increased or decreased need for certain vitamins and minerals with advanced age
(71).
The nutritional intake of older adults may be compromised by many factors
including: socioeconomic pressures, depression, reduced mobility, loneliness, aging
body tissues, physical and mental disabilities, and food and drug interactions
(3,8,9).
Consumption of poor diets is common among individuals over age 65, and
poor diets are increasingly prevalent among those 85 years of age and older (72). A
decline in total energy intake implies micronutrients obtained from these energy
sources will also decrease (70,72,73). The National Health and Nutrition
Examination Survey (NHANES II) reported that mean caloric intakes decreased
below recommended intakes among elderly men and women beginning at
approximately age 50 and continuing through age 74 (74). For example, decreased
zinc intake was reported among older adults who consumed inadequate calories
(23,72). There is concern that decreased nutritional status or dietary intake among
the elderly, especially related to zinc and chromium intake, may lead to increased
insulin resistance and glucose intolerance (17,18,20,58).
Zinc Intake Among The Elderly
Although there is minimal evidence of zinc deficiency among adults in the
United States, some studies have indicated that the elderly have zinc intakes below
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the RDA (75). Using the Food and Drug Administration's Total Diet Study for
1974-1982, 1982-1984, and 1982-86, Pennington et ale (76) reported that mean
intakes of women aged 60 to 65 years were 8.7 mg of zinc daily whereas mean
intakes for men of the same age were 12.9 mg/day. In addition, using the
Nationwide Food Consumption Survey data, Sandstead et ale (23) reported zinc
intakes of elderly were approximately 10.5 mg and 7.6 mg daily for men and
women, respectively.
It has been suggested that zinc deficiency may be underdiagnosed among the
elderly (23). Decreased tissue zinc concentrations have been reported among elderly
populations even though plasma zinc levels were similar to controls. Using 24-hour
recalls, taste acuity tests, and hair zinc concentrations, Hutton et ale (77) determined
that the elderly were at increased risk for zinc deficiency. Estimates of dietary zinc
intake appear to be valid, however, some studies indicate that taste acuity tests and
hair zinc levels are not indicative of zinc status (3,23).
Chromium Intake Among the Elderly
Several studies have reported that the elderly have higher chromium intakes
than young adults, and while chromium intakes were independent of calorie
consumption, they were still below the ESADDI (25). Anderson et ale (6) estimated
that 90% of normal diets in the United States do not provide the minimum intake of
50 ug chromium per day as suggested by the U.S. National Academy of Sciences.
In addition, Anderson reported that chromium absorption was significantly higher in
women than men, which may be a result of lower chromium intake and lower
caloric intakes among women (6).
Anderson et ale (78), chemically analyzed daily chromium intakes and
reported mean daily intakes of approximately 38.8 ug/day for 8 male subjects and
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23.1 ug/day for 11 female subjects, 22 to 65 years of age. These values are below
the ESADDI of 50-200 ug/day (26). In another study, Anderson and Kozlovsky (6)
analyzed the chromium content of self-selected diets by collecting duplicate daily
composites of all foods and beverages consumed by subjects. Chromium content of
dry ashed samples was determined by atomic absorption spectrophotometry. The
reported mean daily chromium intakes were approximately 33 ug/day for 10 male
subjects and 25 ug/day for 22 female subjects, 25 to 65 years of age (6). Among
subjects aged 70 to 85, Bunker et ale (20) analyzed duplicate samples of self-selected
diets of subjects by dry ashing and performing atomic absorption spectrophotometry ,
and reported chromium intakes of 29.8 ug/day for 11 male subjects and 20.1 ug/day
for 12 female subjects.
Supplement Use Among the Elderly
Varying doses of single and multi-nutrient supplements are widely available
in local grocery and drug stores (Appendix A). The use of one or more non-
prescription supplements is common among the elderly (79,80).
Using NHANES I data, Kim reported 22.5 % of subjects qualified as regular
daily supplement users and 10% as irregular users (79). In another study,
evaluation of 20,080 persons aged 18 to 99 years from the 1987 National Health
Interview Survey (NHIS), a cross-sectional, continuing, nationwide survey, reported
that approximately 51 % of respondents consumed a vitamin and/or mineral
supplement within the last year, while 23 % of those consumed supplements daily
(80). In this report, older adults, whites, and women were found to be more likely
to use supplements regularly.
Concerning the use of single-mineral supplements, 13% and less than 0.5%
of the respondents in the 1986 NHIS survey consumed a zinc or chromium
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supplementation product, respectively (48). Zinc supplements were most commonly
consumed as zinc sulfate, gluconate, oxide or chloride while chromium was most
commonly consumed as chromium chloride.
EVALUATION METHODS
Evaluating Dietary Assessment Methods
Dietary assessments are important techniques used to evaluate dietary intakes
of individuals; however, currently there is no ideal method for evaluating dietary
intakes (81). To date, the most widely used methods for assessing dietary intake
include 24-hour recalls, food frequency questionnaires, and food records (81,82).
A 24-hour recall is a retrospective method to evaluate dietary intake in which
the subject relies on memory to recollect food intake from the past 24 hours (83).
One concern with 24-hour recalls is that they may not represent a subjects usual
intake (83); however, Howat et ale (81) reported 24-hour recalls were reliable for
energy and macronutrient intake among 44 women age 18 to 49 years of age.
A food frequency questionnaire is an inexpensive food assessment method
which consists of a record of "usual" or average dietary intake over a specific time
period, such as one to twelve months (84). A food frequency questionnaire contains
information concerning how often most common foods are consumed and standard
portion sizes (85). It has been reported that older adults tend to significantly
underestimate average food intakes using food frequency questionnaires (81,86,87),
which may be due to decreasing short-term memory in advancing years (73,86,88).
Younger adults aged 24 to 51 tend to overestimate food consumption using food
frequency questionnaires (85).
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A food record is a written record of food intake immediately at the time of
consumption. This method requires participation from literate adults who have been
trained to record food intake and estimate portion sizes (81). It is also important
that food records are checked by trained interviewers. Food records can be recorded
for several days. Seven-day records are considered to be the best representation of
usual food intake, but may often be difficult to obtain from subjects (82). However,
Gersovitz et ale (89) reported that food records for more than three days were not
valid with population studies. Three-day food records are generally more accepted
by subjects (82), and are considered an accurate assessment of dietary intake for
moderately sized studies (87). One controversy concerning use of food records is
whether or not to include food intake over weekends due to variation in food intake
from weekend to weekday. St. leor et ale (90) included weekend days in their four-
day food record to include any variation in nutrient intake from weekday to
weekend. Decisions must be made as to which days of the week to record. In a
recent study by Larkin et ale (82), estimation of energy and nutrient intakes from
random three-day dietary records were similar to consecutive three-day dietary
records.
Despite which method is used to evaluate dietary intake, it is important that
the serving sizes reported be valid and reliable (91). Validity accurately assesses
usual intake of subjects while reliability relates to reproducibility or consistency of
reporting data across different measurement periods (81). Individual variation in
estimating portion sizes are immense unless controlled by standard measures.
Therefore it is advantageous to use food models to achieve consistent food portion
from different subjects (92). Moore et ale (92) reported that graduated food models
made from actual food covered in paraffm resulted in reduced frustration among
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interviewers and respondents, as well as increased accuracy in reported serving size,
volume or weight.
Evaluating Anthropometric Measures
Anthropometric measures are used to determine body weight, height, body
fat and lean body mass. As age progresses, changes in anthropometric values are
observed and need to be taken into account in measurement procedures.
Body weight is measured using a standard calibrated scale. A study by
Schoeller (93) indicated total body water tends to decrease with age, indicating
decreases in fat-free mass. Body height can be measured by standing in an upright
position. However, because height tends to decrease with age, an alternate method
to estimate height is knee height stature (94). The long bone below the knee is not
affected by age-related shrinkage and is an accurate measure of overall height among
the elderly. Accurate height estimates are important because height is used in other
estimates of body composition such as determining lean body mass via bioelectrical
impedance analysis (BIA) or body fat via body mass index.
Bioelectrical impedance analysis (BIA) measures electrical conductivity of
fat-free tissue using whole body reactance and resistance to estimate lean body mass
and total body fat. Bioelectrical impedance analysis is an ideal measurement of lean
body mass because it is safe, reproducible, quick and painless, and does not require
any physical demands or invasive procedures (95,96,97). Bioelectrical impedance
does depend on subjects' body water. An individual's hydration status can be
affected by alcohol, diuretics or caffeine, recent exercise or food intake, and
abnormal body temperature (93). Some researchers report that BIA is valid for
older adults even though body water tends to decrease with age, because there is




(98). However, Deurenburg et ale (95) reported that BIA prediction fonnulas
defmed for younger populations overestimated fat free mass (FFM) by
approximately 6 kg due to decreased total percent body water with age among
elderly men and women. BIA age-specific equations are available (99), and the
choice prediction formula for estimation of FFM among the elderly comes from a
study by Deurenburg et ale (95) who measured body composition in 35 men and 37
women aged 60 to 83 years.
Body mass index provides a reasonable estimate of body fat if weight and
height measures are valid (100). Body mass index is calculated as weight
(kg)/height (meters)2 (101,102). Deurenburg et al. (102) reported that BMI
correlates with body fat among younger adults, but due to fat redistribution with
age, as well as decreases in lean body mass and height, BMI may be misleading
among older adults. However, Micozzi et ale (100) reported that BMI is reliable
among the elderly. Body mass index values of greater than 27.8 for men and 27.3
for women indicate the person is 20% overweight whereas values between 22.7 to
27.8 for men and between 22.4 to 27.3 for women are considered to be within





This study was approved by the Institutional Review Board (IRB) for human
subject research at Oklahoma State University (Appendix B). A randomized, block
experimental design consisting of three treatment groups, and four measurement
periods was used for this study. Male and female subjects were randomly assigned
to one of three experiment groups 1) placebo, 2) chromium supplementation or 3)
zinc supplementation. There were 8 subjects per experimental group. Data were
collected at baseline, after four and eight weeks of supplementation and four weeks
after supplementation ended.
The principal investigators and research assistants involved in data collection
for the study received training on laboratory safety, biological hazard disposal and
radioisotope handling.
Subjects
After approval by the Oklahoma State University IRB, subjects were
recruited by announcement through local physicians' offices, college and university
mailings, local newspaper and contacts with senior citizen organizations (Appendix
C). Subjects reviewed and signed an informed consent prior to participating in the
research study (Appendix D). Twenty five volunteers over the age of 50 who were
free of chronic disease, not taking medication to lower blood cholesterol and who
were not attempting to gain or lose weight were included in the study. Originally, it
was intended that subjects' plasma cholesterol concentration be above 240 mg/dl to
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be admitted into the study, but the majority of the subjects did not meet this
guideline. Four women who were on honnone replacement therapy were included
in the study, two were in the zinc supplemented group and two were in the
chromium supplemented group. One subject was omitted from the study because he
was nine years younger than other subjects. Another subject was omitted due to a
high ferritin concentration which may be indicative of hemochromatosis, a condition
which may lead to development of non-insulin dependent diabetes (103). However,
Dinneen et ale (103) also reported that non-insulin dependent diabetes is not typically
associated with iron overload, therefore, two subjects with ferritin concentrations
indicative of iron overload were not omitted.
Twice each day during eight weeks of the study, subjects consumed a lactose
placebo or a supplement containing either zinc (as zinc sulfate) or chromium (as
chromium chloride). Subjects were instructed to take one capsule each morning and
one each evening with meals. Subjects received a four week supply of capsules at
the baseline measurement period. Subjects returned any capsules that were not
consumed during the first four weeks of supplementation at the second measurement
period. At the second measurement period, subjects received a second four week
supply of capsules. Subjects returned any capsules that were not consumed during
the second four weeks of supplementation at the third measurement period. During
each measurement period, subjects kept a three-day written food record. At each
measurement period, each subject also completed a health questionnaire and
participated in anthropometric measurements and blood collection.
Supplements
Supplements for this study were prepared in the Nutritional Sciences
Department laboratory at Oklahoma State University. Number two gelatin caps
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(Apothecary Products, Inc., Burnsville, Minnesota) were ftIled using a gelatin
capsule filling machine (Quanterron, Inc., Burnsville, Minnesota). Placebo capsules
contained approximately 0.25 grams (g) lactose.
The chromium supplement consisted of .8611 g of CrC13·6H20 in 420 g
lactose, so that 0.25 g of the chromium supplement mixture was calculated to
contain 100 micrograms (ug) chromium as chromium chloride. The lactose and
chromium chloride were mixed together for seven hours in a ball mill to ensure even
distribution of the chromium chloride in lactose.
The zinc supplement was prepared in the same manner as the chromium
supplement. The zinc supplement consisted of 110.7206 g of zinc sulfate
(ZnS04·7H20) in 420 g lactose, so that .25 g of the zinc supplement mixture was
calculated to contain approximately 15 milligrams (mg) zinc as zinc sulfate in
lactose.
Due to hydration, the analyzed supplements' mineral concentrations were
lower than calculated values. Therefore, the amounts of chromium chloride and
zinc sulfate were adjusted and supplement mixtures were remixed to adjust the
mineral concentrations of the supplements.
In order to evaluate the accuracy of the supplements, four capsules from each
supplement group were chosen at random and analyzed for chromium and zinc
content using an atomic absorption spectrophotometer, Model 5100pe (Perkin-
Elmer Corp., Norwalk, CT). Supplement and capsules were wet and dry ashed
using a modification of the Hill et ale (104) method. The average analyzed
chromium content of the chromium supplements was 119.66 ug per capsule. The
average analyzed zinc content of the zinc supplement was 15.18 mg per capsule.
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Questionnaire
1. Health information questionnaire:
Prior to beginning the study, each subject was interviewed regarding
information pertaining to past medical history, type of special diet, current
medication, dietary supplements used in the past six months, recent serious illness or
surgery, serum cholesterol concentrations, exercise, and family history of elevated
cholesterol or heart disease (Appendix E).
2. Monthly data collection form:
Each subject completed a monthly data collection form at each of the four
measurement periods. The monthly data collection form consisted of questions
pertaining to presence of cold, flu or other illnesses in the last month, continuation
of supplementation in the presence of illness if any, or a change in the exercise
pattern (Appendix F).
DATA COLLECTION
Height, Weight, and Skinfold Measurements
Subject's standing height was measured at the first and third measurement
periods. With the subject standing erect against the wall with barefoot heels
together, a scaled rule attached to the wall was read to the nearest 1/4 inch.
Subject's body weight was measured at all four measurement periods using a
calibrated beam balance scale (Continental Co., Chicago). Accuracy was read to the




Bioelectrical impedance is used to measure a subject's body fat. Body fat
was measured at the frrst and third data collection periods by a research assistant
trained in the procedure. The bioelectric impedance model used was Biodynamics
Model 310 Body Composition Analyzer (Chattanooga Corporation, P.O. Box 4287,
Chattanooga, TN 37405).
The subjects were briefed on the bioelectrical impedance procedure and then
asked if any heart condition or pacemaker existed. If so, this procedure was
eliminated from the data collection. The subjects were assumed to be in adequate
hydration status and were measured after a 12-hour fast. Subjects were measured
twice at each collection period using new electrodes for each measurement to ensure
accuracy. The measurements were then averaged.
Deurenburg et ale (95) report a prediction formula, applicable to those
persons aged 60 and above, for estimation of fat-free mass (FFM) from bioelectrical
impedance and anthropometric variables as:
FFM (kg) = (0.671 x 104 x H2/R) + 3.1S + 3.9
where H is height (m), R is resistance (ohms), and
S is gender (females, 0; males, 1)
The procedure for bioelectrical impedance detennination is found in
Appendix G.
Knee Height
Often stature decreases with age or osteoporosis. Knee height measurement
can be used to estimate stature of adults 60 to 90 years old. It also can be used with
other anthropometric measures to predict weight. The knee height procedure is a
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reliable estimate of stature when used to adjust body composition measurements
included in bioelectrical impedance (94).
Subjects' knee height was measured during the second collection period.
Measurements were performed in duplicate and later averaged. Measurements were
read to the nearest 0.5 centimeter (cm).
The model used was the Ross Knee Height Caliper (1989), Ross
Laboratories, Columbus, Ohio 43216. The procedure for knee height collection is
found in Appendix G. A diagram of the knee height procedure is found in
Appendix H. A nanogram or prediction equation can be used to determine height.
Equations were provided by Ross Laboratories, Columbus, Ohio 43216, distribution
# 50452, 1989. The gender and age specific equations are as follows:
Stature for men= [2.03 x knee height(cm)] - [0.04 x age(yr)] + 64.19
Stature for women= [1.83 x knee height(cm)]-[0.24 x age(yr)] + 84.8 (105).
Blood Collection
Subjects fasted for 12 hours prior to each blood collection. Due to variations
in plasma mineral concentrations with the time of the day, all blood collections were
performed between 7:30 and 9:30 AM. Blood collection was performed by a
phlebotomist. The procedure for blood collection can be found in Appendix I.
Dietary Records
Before beginning the study, subjects were trained by a registered dietitian for
recording three day dietary intakes. A modification of the Moore (92) method was
used for food models. Food models constructed of dried beans wrapped in netting
were used to illustrate 1 cup, 1/2 cup and 1/3 cup portion sizes. Wooden blocks
were used to illustrate 3 oz meat!cheese portions. Registered dietitians or research
28
assistants reviewed the 3-day dietary records descriptions, corrections, and additions
with each subject on the day of blood collection. The dietary data were recorded on
three consecutive weekdays prior to each measurement period (Appendix 1).
Dietary Record Analysis
The three-day dietary food records were analyzed using the Food Processor
Plus program (version 5.03, ESHA Research, Salem OR). Diets were analyzed for
each set of three day dietary records. Data used in this study from the diets
analyzed using Food Processor Plus program included kilocalories, protein,
carbohydrate, fiber, total fat, zinc, percent of calories from protein, percent of
calories from carbohydrate, and percent of calories from fat.
BIOCHEMICAL ANALYSES
Glucose
Plasma glucose was measured by a quantitative, enzymatic (glucose oxidase)
determination method (Sigma Diagnostics procedure No. 510, St. Louis, MO). At
each measurement collection period, analysis was performed with three hours of
blood collection. All samples were performed in duplicate and then averaged. If
duplicate values were not within 5% of each other, the analysis was repeated. This
method was modified to use smaller amounts of plasma that could still be detected
by the spectrophoto-meter (Appendix K). All tubes were covered with foil to
prevent exposure to light and incubated at room temperature for 45 minutes.
Absorbances of the standard and test samples were read against a blank as referenced
at 450 run using a Gilford spectrophotometer (Response Series, Ciba Corning
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Diagnostics, Corp., Oberlin, OH). All readings were completed within 30 minutes
of initiating the procedure.
Albumin
Serum albumin was measured by a quanitative, colorimetric determination
method using the bromocresol purple method (Sigma Diagnostics procedure No.
625, St. Louis, MO). Absorbance was read using a visible lamp at 600 nm.
RADIOIMMUNOASSAY
Insulin
Serum insulin was measured by double antibody radioimmunoassay (RIA).
Insulin determination is based on the ability of an antibody to bind a fixed amount
radioactive isotope. Frozen serum samples were thawed and kept on ice for
analysis. Thawed samples were vortexed for five seconds prior to sample analysis.
All tests were run in duplicate except non-specific binding tubes (NSB), which were
run in quadruplicate. For each sample, duplicate values were averaged. If duplicate
values were not within 5% of each other, samples were reanalyzed. The Equate
(Equate RIA, South Portland, ME) option 1 procedure was followed. Insulin tracer
and antiserum was added to all tubes using an Eppendorf repeating pipette. All
tubes were vortexed, covered with parafilm, and incubated at room temperature for
ten minutes. All tubes were centrifuged at 4 degrees Celsius at 1500 x g for 10
minutes. The supernatant of each tube was decanted using a blotting technique, so
that only the pellet remained. The tubes were counted for one minute using a




Serum ferritin was measured quanitatively by double antibody RIA method
(Diagnostic Products Corp., Los Angeles, CA). Samples were counted for one
minute using a gamma counter (Packard Cobra II, Auto Gamma, Packard
Instrument Co., Meriden, CT)
DATA ANALYSIS
Data were analyzed using the Statistical Analysis System (SAS Inst. Inc.,
Cary NC, 1987) version 6.06. Treatment means at baseline, four and eight weeks
supplementation and four weeks post supplementation were compared to the placebo
using the SAS General Linear Model procedure, significant differences were
determined by Least Squared Means. Correlation coefficients were determined at
baseline between dietary parameters and plasma glucose and serum insulin




The subjects in this study were independently living volunteers from the
community of Stillwater, Oklahoma. Initially, twenty-nine subjects participated in
the study; however, three dropped out before completion. Two subjects completed
the study but were not included in the data analysis, because one subject was outside
of the age range of the other subjects, and another had an extremely elevated initial
ferritin concentration of 752 ng/ml. Therefore, twenty-four subjects were included
in the data analysis. Of these twenty-four subjects completing the study, there were
8 subjects per supplement group. Two subjects in the zinc supplement group did not
have bioelectrical impedance measurements administered due to cardiac
irregularities. One subject in each group, placebo, chromium, and zinc, missed the
second data collection period.
Description of Subjects by Gender
For the entire sample population, there were 11 males and 13 females with a
mean age of 65 years, and an age range of 51 to 82 years of age. There were 5, 2,
and 4 males and 3, 6, and 4 females in the placebo, chromium and zinc supplement
groups, respectively (Table 1). Male subjects had a mean age of 62 years, mean
height of 70 inches, mean weight of 179 pounds, and a mean body mass index
(BMI) of 25.8 (wt/ht2). Female subjects had a mean age of 68 years, mean height
of 63 inches, mean weight of 142 pounds, and a mean BMI of 25.0 (wt/ht2).
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TABLE 1
Subjects' Initial age, body weight, height, and body mass index (BMI)·
Placebo Chromium Zinc
Sample size (n=)
Total 8 8 8
Male 5 2 4
Female 3 6 4
Age (yrs)
Total 63 ±4a 68±4b 64:1: 2&
Male 58± 38 70 ± 12b 63 ±4b
Female 72±7 68:1:4 65:1:3
Body Weight (Ib)
Total 164 ± 13 159:1: 14 155 ± 12
Male 169:1: 14& 194 ± 13b 183 :I: gb
Female 155 ± 29 147 ± 16 126 :I: 10
Height (in)
Total 68.0 ± 1.58 64.0 ± 1.2b 66.1 ± 1.38
Male 70.4 ± 1.2a 68.5 ± O.5b 69.3 ± O.Sa
Female 64.0 ± 1.7 62.5 ± 0.8 63.0 ± 1.1
BMI (kglm2)
Total 24.7 ± 1.58 26.9 ± 1.8b 24.5 ± 1.3&
Male 23.9 ± 1.38 29.1 ± 1.Sb 26.7 ± I.le
Female 26.3 ± 3.6a 26.2 ± 2.3a 22.3 ± I.Sb
*means ± standard error
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Differences at Baseline Between Supplement Groups by Gender
Subjects' mean age, height, weight and BMI by gender and supplement
groups are reported in Table 1. Body weight for all groups was considered to be
within desirable ranges. Mean body mass index values for males in the chromium
supplement group were considered overweight while placebo, zinc supplement
groups, and all females were within desirable weight.
Significant differences were observed among males and females between
placebo, chromium and zinc supplement groups for initial age, body weight, height,
and BMI values. Males in the chromium supplement group were significantly older
than males in placebo or zinc supplement groups (Table 1), while no significant
differences were observed for females for age. Males in the chromium and zinc
supplement groups had significantly higher body weights compared to placebo
(Table 1); however, no significant differences were observed for height in females.
Males in the chromium supplement group were significantly shorter
compared to placebo and zinc supplement groups (Table 1); however, no
significance was observed for females.
Mean BMI values were significantly different for males in each supplement
group (Table 1). Females in the placebo and chromium supplement groups had
significantly higher mean BMI values compared to the zinc supplement group (Table
1).
Subjects' mean initial plasma glucose, serum insulin, ferritin and albumin
concentrations by gender and supplement groups are reported in Table 2. All initial
mean values for plasma glucose, serum insulin, ferritin and albumin concentrations
were within normal parameters for males and females; however, significant
differences were observed among males and females between placebo, chromium
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TABLE 2




Total 93 ±2a 106 ± 7b 92±3a
Male 90±3a 127 ± 6b 94±4a
Female 96±4 98±6 90±5
Insulin (JlJl/ml)
Total 22± 3 24±2 20± 1
Male 19±2a 28 ± Ib 20± 18
Female 27± 5a 23 ±2b 21 ±2b
Ferritin (nglml)
Total 133 ± 37 122 ± 49 106 ± 28
Male 155 ± 588 316 ± 122b 158 ± 428
Female 97 ± 168 57 ± lIb 55±6b
Albumin (g1dl)
Total 4.8 ± 0.1 4.7 ± 0.2 4.7±O.2
Male 4.9 ± 0.1 5.2 ± 0.1 4.8± 0.4
Female 4.7± 0.2 4.5 ± 0.2 4.5 ± 0.1
*means ± standard error
Different superscript letters within a row are significnatly different from one another
(p<O.05)
and zinc supplement groups for initial plasma glucose, serum insulin and ferritin
concentrations.
Mean initial plasma glucose concentrations were significantly higher among
males in the chromium supplement group compared to males in the placebo and zinc
supplement groups. However, no significant differences were observed for mean
initial plasma glucose concentrations among females between supplement groups.
(Table 2).
Mean initial serum insulin concentrations were significantly higher in males
in the chromium supplement group compared to males in the placebo and zinc
supplement groups. Females in the placebo group had significantly higher mean
serum insulin concentration compared to females in the chromium and zinc
supplement groups (Table 2).
Mean initial ferritin concentration was significantly higher among males in
the chromium supplement compared to males in the placebo and zinc supplement
groups. This difference is due to the two male subjects in the chromium supplement
group who had elevated ferritin concentrations, but who were not omitted from the
study. Females in the placebo group had significantly higher initial mean ferritin
concentration compared to females in the chromium and zinc supplement groups
(Table 2). No significant differences were observed for serum albumin
concentrations for either males and females between supplement groups (Table 2).
No significant interaction was observed over time between supplement
groups and gender or age with plasma glucose or serum insulin concentrations using
repeated measures analysis of variance. Therefore, all further data analyses were
analyzed only by supplement groups, and not by gender or age.
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Differences at Baseline between Supplement Groups
At baseline the chromium supplement group had a significantly higher mean
age than placebo or zinc supplement groups (Table 1). There were no initial
significant differences for initial mean body weight between the placebo, chromium
or zinc supplement groups (Table 1). The chromium supplement group also had
significantly lower height and a significantly higher BMI compared to placebo and
zinc supplement groups (Table 1).
At baseline there were no significant differences between the placebo,
chromium and zinc supplement groups for initial mean serum insulin, ferritin or
albumin concentrations (Table 2). Initial mean plasma glucose concentration was
significantly higher in the chromium supplement group compared to placebo and
zinc supplement groups (Table 2).
Initial mean fasting plasma glucose concentration for all groups in this study
were similar to mean fasting plasma glucose concentrations of 97 mg/dl reported by
Offenbacher et ale (16) among 24 combined diabetic and nondiabetic subjects, mean
age 78 years. Initial mean plasma glucose concentrations among the placebo and
zinc supplement groups were similar to plasma glucose concentrations of 5.11
mmol/L (92 mg/dl) observed by Hermann et ale (106) among 12 subjects aged 60
and older with elevated cholesterol concentrations of greater than 6.21 mmol/L. Lui
et ale (59) reported initial mean fasting glucose concentrations of 101 mg/dl among
27 women aged 40 to 75 years of age, of whom 15 had nonnal glycemic control and
12 were hyperglycemic.
In the same study by Offenbacher (16), the initial mean serum insulin
concentration of 11 uU/ml was lower than the initial mean serum insulin of 22
uUIml reported for all subjects in this study. However, initial mean fasting insulin
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concentration reported by Lui et ale (59) was 27 uU/ml, which was higher than the
reported initial mean insulin concentration of 22 uU/ml observed in this study.
Effects of Eight Weeks Supplementation on
Plasma Glucose and Serum Insulin
An increase of approximately 7 % was observed in assay controls during the
second measurement period compared to the first, third and fourth measurement
periods. As a result, effects observed after four weeks supplementation (second
measurement period) may not be due to supplementation, but rather to malfunction
of the instrument used for analysis. Therefore, data after four weeks
supplementation are not presented.
Chromium. In this study, a significant decrease (p=.0189) was observed in
mean plasma glucose concentrations in the chromium supplement group after eight
weeks supplementation compared to the placebo. However, mean plasma glucose
concentration in the chromium supplement group was similar to the baseline
concentration at four weeks post supplementation (Table 3). These data indicate that
chromium supplementation resulted in a beneficial decrease in plasma glucose
compared to the placebo, and that values returned to initial concentrations at four
weeks post supplementation suggesting better to no carry over effect of the
supplemental inorganic chromium.
Lui et ale (59) also observed a decrease, although not significant, in mean
fasting glucose concentration after 3 months supplementation with 4 ug of chromium
as brewer's yeast. However, Uusitupa et ale (66) observed that mean fasting blood
glucose concentration remained unchanged among subjects supplemented for six
weeks with 200 ug chromium as chromium chloride solution compared to the
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TABLE 3
Chromium supplementatiolJ effects on plasma glucose
and serom insulin by measurementperiod
Glucose· Change from Insulin· Change from
(mgldl) baseline (JlIl/mI) baseline
Placebo
Baseline (n=8) 93 ±2 22±3
8 weeks (0=8) 93 ±4 0 26±6 +4
12 weeks (0=8) 94±2 +1 22±3 0
Chromium
Baseline (n=8) 106±6 24±2
8 weeks (n=8) IOO± 7 -6·· 24±3 0
12 weeks (0=8) I07± 6 +1 25±3 +1
·means ± standard error
•• significant change from baseline, supplemented group versus placebo, p<O.OS
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control. However, I-hour blood glucose concentration was significantly decreased
in the chromium supplement group compared to the control I-hour blood glucose
concentration.
Although not significant, an increase in mean serum insulin concentration
was observed in our study in the placebo group compared to the chromium
supplement group. Mean serum insulin concentrations were similar to baseline at
four weeks post supplementation for both the placebo and chromium supplement
groups.
In the same study as mentioned previously, Uusitupa et ale (66) also observed
an increase, although not significant, in fasting mean serum insulin concentration in
the placebo supplement group after 6 weeks supplementation with 200 ug chromium.
However, in a study by Lui et ale (59), a significant decrease from 27 uU/ml to 13
uU/ml was observed in mean fasting insulin concentration among 27 women after 3
months supplementation with only 4 ug chromium from brewer's yeast. The
difference observed by Uusitupa could be due to the form of chromium used. While
not apparent in our study, Riales et al. (65) observed a decrease, although not
significant, in mean insulin concentration among 7 healthy men aged 31 to 60 after
12 weeks of 200 ug chromium supplementation as chromium chloride compared to
placebo. This observed difference could be due to the longer supplementation
period by Riales' study.
Zinc. In this study, mean plasma glucose concentration among subjects in
the zinc supplement group did not significantly change after eight weeks
supplementation compared to the placebo. However, there was a significant
increase (p= .0004) in mean plasma glucose concentration four weeks post
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supplementation in the zinc supplement group compared to the placebo (Table 4).
This increase may be due to the removal of the zinc supplement.
A significant decrease (p=.0254) in mean serum insulin concentration was
observed among subjects in the zinc supplement group after eight weeks
supplementation compared to the placebo. Mean serum insulin concentrations were
similar to baseline at four weeks post supplementation for both the placebo and zinc
supplement groups (Table 4), indicating concentrations returned to baseline within
four weeks post supplementation. It is possible that a longer zinc supplementation
period could result in a greater decrease in serum insulin concentration compared to
the placebo. Longer supplementation may also result in adaptation or return to
baseline values while on the supplement.
There are few studies concerning effects of zinc supplementation in humans
on serum insulin concentrations. However, there are studies involving zinc deficient
animals. Glucose intolerance during a glucose challenge, as well as insulin
resistance has been observed in zinc deficient animals (18). However, no significant
changes were observed by Quarterman et ale (48) in glucose tolerance curves and
mean plasma insulin concentration among zinc deficient animals compared to control
animals. A significant decrease in mean serum insulin concentration was also
observed by Huber et ale (48) among zinc deficient rats compared with pair fed
controls.
Dietary Intakes at Baseline
Mean initial caloric intakes by gender within supplement groups are
presented in Table 5. The percentages indicate the majority of our subjects
consumed less than 100% of the recommended energy intake (REI) for their age.
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TABLE 4
Zinc supplementation effects on plasma glucose
and serum insulin by measuremelJtperiod
Glucose· Change from Insulin· Change from
(mg/dl) baseline (pJi/ml) baseline·
Placebo
Baseline (0=8) 93 ±2 22±3
8 weeks (n=8) 93 ±4 0 26±6 +4**
12 weeks (0=8) 94±2 +1 22±3 0
Zinc
Baseline (n=8) 92±3 20± 1
8 weeks (n=8) 92±6 0 19± 1 -1
12 weeks (n=8) 101 ± 5 +9** 21 ± 2 +1
*means ± standard error
•• significant change from baseline, supplemental group versus placebo, p<0.05
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TABLES
Mean initial caloric intake·
Gender Placebo Chromium Zinc
Male
n= 5 2 4
daily calories 2187 ± 176 1988 ± 20 1648 ± 181















• means ± standard error
% ofREI =Percent ofRecommended Energy Intake for adults over age 51 (3)
However, only the male and female subjects in the zinc supplement group consumed
less than 75% of the REI.
Mean initial total daily calories, percent of daily calories from carbohydrate,
protein and fat, total fiber and zinc intakes by placebo, chromium and zinc
supplement groups are reported in Table 6. A significant difference in mean initial
total calorie intake was observed between supplement groups. Subjects in the
placebo group consumed significantly higher mean initial calories than subjects in
the chromium or zinc supplement groups (Table 6). Subjects in the placebo groups
also consumed significantly lower mean initial percentage of daily calories from
carbohydrate than subjects in the chromium or zinc supplement groups (Table 6).
However, the mean initial percent daily calories from carbohydrate consumed by the
placebo group was similar to the Food and Nutrition Board's current
recommendations that over half of all daily calories be supplied by carbohydrate (26)
while the mean initial percent of calories from carbohydrate consumed by the
chromium and zinc supplement groups were similar to the Senate Select Committee
on Nutrition and Human Needs recommendations that 58 percent of all calories
come from carbohydrate (107).
No significant differences were observed between supplement groups in mean
initial percent of daily calories from protein or total fat (Table 6). The mean initial
percent daily calories from protein consumed by all groups was higher than the 12%
suggested in the Dietary Goals for Americans (107). In addition, the mean initial
total fat consumed was similar to the 30% of calories from fat suggested by the US
Dietary Goals for Americans (107).
The placebo group did have a significantly higher mean initial fiber intake
compared to the chromium and zinc supplement groups (Table 6). Mean initial fiber
intake in the placebo group was similar to recommendations that Americans
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TABLE 6
Initial Dietary intakesfor placebo, chromium, and zinc supplementedgroups·
• means ± standard error
% CHO = percent daily calories from carbohydrate
% PRO = percent daily calories from protein
% FAT = percent daily calories from total fat.





2082 ± 145a 1643 ± 226b 1518 ± I07b
51 ±2a 55 ± 3b 55 ±3b
17 ± I 17±3 18 ± 1
31 ± 1 30±3 29±2
24±2a 19±2b 16± Ib








consume 20 to 35 grams of dietary fiber daily (108); however, the chromium and
zinc supplement groups consumed less than this recommendation (Table 6). Mean
initial dietary zinc intake in the zinc supplement group was significantly lower than
the placebo and chromium supplement groups (Table 6).
Dietary Intakes Over Time Among Supplement Groups
Mean total daily calories, percent of daily calories from carbohydrate,
protein and fat, fiber and zinc intakes were analyzed over time within the placebo,
chromium and zinc supplement groups. No significant differences were observed
over time among the placebo, chromium or zinc supplement groups for any dietary
parameters, with the exception of total daily calories, which significantly increased
in the zinc supplement group (p= .0397) after eight weeks supplementation. Mean
total caloric intakes in the zinc supplement group were 1518, 1739 and 1432 calories
for baseline, 8 weeks supplementation and 4 weeks post supplementation,
respectively.
Correlations between Dietary Intakes at Baseline and
Plasma Glucose and Serum Insulin in Supplement Groups
Correlations between baseline dietary intakes and baseline plasma glucose
and serum insulin concentrations were determined for the total sample (Table 7).
Correlation coefficients were considered significant if probability values were less
than 0.05 (Table 7).
A significant positive correlation was observed between initial serum insulin
and initial plasma glucose concentration (r= .49306, p= .00(1). These data indicate
that as serum insulin concentrations increased, plasma glucose concentrations
increased and, conversely, as plasma glucose concentrations increased, serum insulin
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TABLE 7
Con-elation coejJicients between dietary intakes at baseline and plasma glucose and serum insulin concentrations
Calories % CHO % PRO % FAT Fiber Zinc Ferritin Albumin Weight
Glucose
r 0.046 -0.178 0.085 0.211 -0.005 0.281 0.376 0.066 0.396
.P NS NS NS 0.0390 NS 0.0056 0.0002 NS 0.0001
Insulin
r 0.268 -0.118 -0.174 0.222 0.099 0.130 0.110 -0.233 0.606
p 0.0082 NS NS 0.0296 NS NS NS 0.0222 0.0001
r = correlation coefficient
p = statisical probability
NS = no significant difference
% CHO = percent daily calories from carbohydrate
% PRO = percent daily calories from protein
% FAT =percent daily calories from total fat
Weight = body weight
~
~
concentrations also increased. An increase in glucose concentrations will lead to an
increase in insulin concentrations, which may be a consequence of insulin resistance
(109).
No significant correlations were observed between initial total daily calories
from carbohydrate or protein and initial plasma glucose or serum insulin
concentration (Table 7). However, initial percent daily calories from fat was
positively correlated with initial glucose and serum insulin concentrations (Table 7).
This indicates that as total fat in the diet increased, plasma glucose and serum insulin
concentrations also increased. In a study by Mayer et ale (110), dietary fat was also
positively related to fasting insulin concentrations among 272 sets of female twins
aged 30 to 84 years of age, mean age 51. However, in this study by Mayer, an
estimated 1511 calories per day was reported. The mean percentage of daily
calories from fat was higher than in our study (38%), while percent daily calories
from carbohydrate was lower (43 %) than in our study. Percent daily calories from
protein was similar in both studies. Chen et ale (69) also observed that insulin
sensitivity improved when non-diabetic elderly subjects of desirable weight
consumed diets higher in carbohydrate than their typical intakes.
No significant correlations were observed between initial fiber intake and
initial plasma glucose or serum insulin concentrations (Table 7). A significant
positive correlation was observed between initial zinc intake and initial ferritin
concentration with plasma glucose concentration; however, no significant
correlations were observed between these parameters and serum insulin
concentration (Table 7).
A significant negative correlation was observed between initial albumin
concentration and serum insulin, indicating that as albumin concentrations
decreased, serum insulin concentrations increased. However, no significant
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correlation was observed between initial albumin concentration and initial plasma
glucose concentration (Table 7).
Significant positive correlations were observed between initial body weight
with initial plasma glucose and serum insulin concentrations, indicating that plasma
glucose and serum insulin concentrations are increased among persons with higher
body weights (Table 7). Insulin resistance is common among subjects with body
weights that are 20% above their desirable weights. Improvements in insulin





The purpose of this study was to investigate the effects of eight weeks
chromium or zinc supplementation on plasma glucose and serum insulin
concentrations in adults age 50 and above. This study was conducted in the spring
and early summer of 1993, using twenty-four adult volunteers from the community
of Stillwater, Oklahoma.
Subjects were randomly assigned to one of three supplement groups. The
placebo group (n=8) consumed 0.25 mg/day lactose in a supplemental capsule, the
chromium supplement group (n=8) consumed supplements containing 241.32 ug
chromium per day as chromium chloride, and the zinc supplement group (n=8)
consumed supplements containing 30.36 mg zinc per day as zinc sulfate.
Supplementation lasted for eight weeks. Subjects consumed independently chosen
diets throughout the study.
Blood samples were obtained at baseline, after four and eight weeks
supplementation and four weeks post supplementation. Anthropometric data,
including height, weight, bioelectrical impedance, and knee height were obtained at
specific measurement periods.
Changes in plasma glucose and serum insulin concentrations after eight
weeks supplementation and four weeks post supplementation were compared to
changes in the placebo using SAS General Linear Models procedure. Significant
differences were determined by Least Squares Means.
The initial dietary intakes from three day averages were used for dietary
analysis. Dietary parameters included in diet analysis for placebo, chromium and
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zinc supplement groups across measurement periods included total daily calories,
percent daily calories from total carbohydrate, protein, and fat, fiber and zinc
intakes. Correlation coefficients were also determined between initial dietary intakes
and initial plasma glucose and serum insulin concentrations using SAS.
Missing data in the nutritional analysis program placed limitations on
interpretations that can be made. Many foods that were added from label
information had missing mineral or complex or simple carbohydrate information.
Also, chromium was not included in the nutritional database.
In this study, we observed a beneficial decrease in plasma glucose after eight
weeks chromium supplementation compared to the placebo and a significant
decrease in serum insulin concentrations after eight weeks zinc supplementation
compared to the placebo. We also observed positive correlations among initial
dietary parameters with initial plasma glucose and serum insulin concentrations.
RECOMMENDATIONS
The author recommends the following:
1. Evaluation of a larger sample at low and high extremes of mineral status.
2. Evaluation of zinc and chromium supplementation using a diabetic
population.
3. Supplementation for a longer time period, which may allow mineral
status to better adapt to intake.
4. Supplementation with both zinc and chromium to determine effects of
interaction.
5. Use of a food analysis program that contains chromium values, more
accurate complex carbohydrate, simple sugars and other missing data.
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6. Obtaining a detailed evaluation of activity levels to better determine
individual calorie needs.
7. Training subjects as a group to record diet records.
8. Use of a pocket-sized food diary, to be carried with subjects at all times,
to ensure compliance in recording all foods consumed, at or away from home.
CONCLUSIONS
Supplementation with chromium or zinc may have a beneficial effect on
plasma glucose and serum insulin concentrations among adults aged 50 and older.
Hypothesis one stated that there will be no significant relationship between
initial dietary intake and initial plasma glucose or serum insulin concentrations in
adults age 50 and above. As seen in Table 7, significant correlations were observed
between initial dietary intake with plasma glucose and serum insulin. Therefore, the
first null hypothesis was rejected.
Hypothesis two stated that there will be no significant effect due to eight
weeks zinc supplementation on plasma glucose concentration in adults age 50 and
above. There was no significant effect due to eight weeks zinc supplementation on
plasma glucose concentration. Therefore, the second null hypothesis was accepted.
Hypothesis three stated that there will be no significant effect due to eight
weeks zinc supplementation on serum insulin concentration in adults age 50 and
above. As seen in Table 4, a significant decrease was observed after eight weeks
zinc supplementation in serum insulin concentration compared to the placebo group.
Therefore, the third null hypothesis was rejected.
Hypothesis four stated that there will be no significant effect due to eight
weeks chromium supplementation on plasma glucose concentration in adults age 50
and above. As seen in Table 3, a significant decrease was observed after eight
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weeks chromium supplementation in plasma glucose concentration compared to the
placebo. Therefore, the fourth null hypothesis was rejected.
Hypothesis five stated that there will be no significant effect due to eight
weeks chromium supplementation on serum insulin concentration in adults age 50
and above. There was no significant effect due to eight weeks chromium
supplementation on serum insulin concentration. Therefore, the fifth null hypothesis
was accepted.
Due to the results observed in this study, it appears that a diet adequate in
chromium and zinc may beneficial in achieving glucose control and increasing
insulin sensitivity among aging adults. Additionally, diets that provide a good
balance of carbohydrate, protein and fat, and adequate nutrients may have a positive
influence on plasma glucose and serum insulin concentrations among older adults.
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Availability of Mineral in Over-the-Counter Supplements*
Supplements containing copper, chromium and zinc are readily available over the
counter. Single nutrient supplements of chromium and zinc are available in nearly
every grocery and drug store as well as in discount stores in Stillwater. The doses
of minerals are 200 ug for chromium and range from 35 to 100 mg for zinc. In
addition higher amounts of over the counter zinc can be ordered by request. Copper
was found as a single nutrient in only one location in Stillwater; the amount of
copper in this supplement was 2 mg with the recommended dose of one tablet per
day.
Multi-nutrient supplements containing all three minerals with varying amounts of
each are widely available in all the above locations. "Stress" and "high potency"
supplements generally contain 3 mg of copper, and varying amounts of zinc. Not
all of these supplements contain chromium. The range of chromium found in the
multi-nutrient supplements was 15 to 1000 ug. For copper, the range was 2 to 3
mg, and for zinc the range was from 15 to 50 mg.
Some of the supplements suggested taking 2 to 3 packets or tablets per day which
would increase the copper to 4-6 mg, zinc to 80-120 mg, and chromium to 400 ug
per day.
Representative specific supplements are included on the next page. This listing does
not include all of the supplements available but does include those with both the low
and the high levels.
*Over the Counter Supplements Available in Stillwater
September 28, 1992.
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Over the Counter SUDolements AV:lil3ble in Slillw3rer
September ~S. 1992
Sialle Nutrient Supplements
Nutrient Br:lnd Amount of Miner~1 Form
Chromium
Soring V:llley 200 ug Chromium picolin3te





ClPS : mg Copper glucon3te
~
Spring Volley SO mg & 100 mg Zinc gluconate
Kat Zinc 100 + S 100 mg Zinc :Imino o.cid
chelate
Thompson Organic SO ml Zinc gluconate
Thompson Zn
Picolinate 3S mg Zinc picolin:lte
Rugby L3bs 200 mg Zinc sulfate
Upshire Smith 220 mg Zinc sulCate






Copper sulf3te 2 mg
Amount of Miner:!1
Spring Volley Athletes .
Copper gluconate
Zinc gluconate
Spring VAlley Stress with Zn
Cupric oxide
Zinc sulfate













APPROVAL FORM FOR INSTITUTIONAL





?rcpasal ':'!.tla: EFFECTS OF SUPPLEMENTATION WITH CHROMIUM, COPPER AND ZINC
ON PLASMA LIPIDS« BONE MtTAaQI,I~M aND T~mlcAmB5 OF TRACE MXm;u[, STATUS rN
ADULTS
i'rincipal Inv••~iq.1:or: ANDREA B. AROUITT/JANICE R. REBMANN
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Oa~.: 10-22-92 HES-Q1-QJ 1
?!:Oc.ssed as: E:.xezapl: ( ) Expedite (
Renewal or Conl:inuaeicn {
Full aoard Review kxl
Approved [xX
Approv.d wieh Prt)vision ( ]
a.ferrae for ReV1sion { 1
Clsapproveci ( )
Approval sca~us SuCjec~ to review by full Ins~itu~1onal Review Board at
nen meec:.inq, 2nd and 4th Thursday of each mont:h.
-------~-~--~~~~---~~----~---~--~~-~----~~-----~-----~------~-~----~-~-~











DO YOU HA VE HIGH BLOOD CHOLESTEROL?
Have you ever wondered what it would be like to be a participant in a research study'!
Would you like to know the effects of nutrient supplements on hlood cholesterol, hone
metabolism and nutritional status'!
We have an opponuniry for you if you meet the following conditions:
Over the age of 55
Not using estrogen replacement therapy or drugs to
control blood cbolesterol
Do not have a chronic disease
Blood cholesterol levels greater than 240 mg/dl
This study is designed to determine the effect of minerals on blood lipids, hone metabolism
and measures of trace mineral status. The study involves participation for 12 week.~ during
which time you will participate in hody composition measurements (height, weight, skin-fold
measurements, and bioelectric impedance), record food intakes and blood collections.
The tirst collection period wiJl be at the beginning of the study to provide haseline data. For
eight weeks you wiJJ take 3 supplement twice a day. The supplement will contain either
lactose, 15 mg zinc, 1.5 mg copper, 100 ug chromium or combinations of these concentrations
of copper/zinc or copper/chromium. Data will be collected after four and eight weeks of
supplementation , and then four weeks after the end of supplementation.
All that is required of you is to record food intakes for three days prior to each data collection,
take the supplement twice daiJy for eight weeks, and come to the Department of NutritionaJ
Sciences at OSU at four week intervals for blood coUection (30 m1 or about 6 teaspoons).
Weight and body composition measurements will be recorded at each data collection period.
We ask that you do not attempt to lose weight or change your usual eating and exercising
habits during this period.
Volunteers completing the study will receive a complementary lunch at Taylors Dinning
Room.
This study has been approved hy the OkJahonJ3 State University Internal Review Board for the
protection of human subjects. ·
-
Sound like fun?!f If you're intere~ted or for further information please contact or tear off
and send this response to:
Andrea B. Arquitt, PhD, RD/LD
Janice R. Hermann, PhD, RD/LD
Department of Nutritional Sciences
425 HES




I am interested in more information on the hlood lipid, bone mineral 'metabolism and trace









Individual's Consent to Participate in Research
Effect of Supplemen.tation with Chromium,Copper and Zinc on Plasma Lipids, Bone
Metabolism and Indicators of Trace Mineral Status in Adults
I,. . : ,voluntarily agree to participate in the above titled research
which IS sponsored by AgncuJture Experiment Station, College of Human Environmental
Sciences at Oklahoma State University.
I understand that:
(1) the purpose of the study is to measure the effect of mineral supplementation on
plasma lipids, bone metabolism and st3tus of other trace minerals in adults;
(2) I wiU receive supplements containing either a placebo or ONE of the fOUo~
minerals or mineral combinations which are equal to or less thaD those av· ble
in over-the-aJODter mineral supplements:
(a) 1.5 mg zinc
(b) 1.5 mg copper
(c) 100 ug chromium
(d) 15 mg zinc plus 1.5 mg copper
(e) 1.5 mg copper plus 100 ug chromium;
(3) I will take one supplement with each morning and evening meal;
(4) I nnderst2nd that these supplements may cause slight nausea if taken on an
empty stomach and that is the reason (or the above statement; however, if I
have any adverse reactions I will contact onc of the principal investigators;
(5) I will be requested to record three days of food intake four times during this study;
(6) during this study period I should attempt to avoid consumption of oysters, and the
following breakfaSt cereals: General Mill's Total (aU varieties) and Kellogg's
Nutri-grain Raisin Bran, Just Right, and Just Right Fruit & Nut;
(7) I will not take any nutrient supplements other than those that are a part of this
study;
(8) a phlebotomist will draw fasting blood samples of 30 m1 (about 6 teaspoons) by
. venipunctme prior to the study, at midpoint and end of the supplementation, and
four weeks foUowing supplementation and that slight bruising or discomfort may
result from the venipuncture;
(9) I understand that this blood will only be used for analyses which involve
lipid status mineral status and bone mineral metabolism and that after these
analyses ar~ performed the remaining blood will be incinerated and that DO
perpetual cell lines will be maintained;
(10) as a reward for participation 3;Dd as an incentive to complete the.~dy, I will
receive one coupon for a complimentary luncheon at the Taylor Dmmg Room at the
end of the study;
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( 11) all records are confidentiaJ and that my name will not be associated with any
repons or data records at the end of tbe stUdy;
(12) participation is voluntary and that I have the right to withdraw from this study at
any time by contacting the principal investigators;
(13) I will withdraw from the project if I need to begin taking medication for my
health during this study;
(14) this researcb is beneficial to the public in that many individuals tlke nuaient
supplements without knowledge of the interactions among the nutrients; and
(15) I may contact Dr. Andrea Arquitt or Dr. Janice Hermann at (40S) 744-.5040
should I wish further information. I may also contact the office of University
Research Services, 00 1 Life Sciences East, Oklahoma State UDiversity, Stillwater,
OK 74078 teJepbone (405) 744-5700.
I have read and fully understand the consent form. I sign it freely and voluntarily. A copy
has been given to me.
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Date -------- Time (am/pm)
Signed _
I certify that I have personally explained all elements of this form to the subject befon:
requesting the subject to sign it.
Signed ~-,..--orr-----,--___r---~---.,..










Subject Number D:tce of Birth ______ R3ce G~nder _























Do you currently t3ke :lny medic3tions on a regular b3sis? _
Specify all drugs taken
(n the last 6 months h3ve ~'OU (:lken :lnv nutrient Idict3ry, supplementS! YES
IF YES. Specify how recently _
How re~ul:lrly _
IF YES. Specify br:1nd :1nd frequency of consumption:
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NO _Have you recently had :l serious illness or surgery? Yes _
Specify
Do you know your cholesterol "number" (concentr:ltion)? YES _ NO _
IF YES, what is it? (otal----- HDL-----
\Vhen did you learn you had high blood cholesterol 7 _____(year)
_____(don't rec:lll)
Do you regularly exercise? Yes No _
~hat type of exercise do you do? ~~~~~~~~~~~~~~~~~~~~~~~~
How many times :l week do you exercise? _~~_~_
What length of time do you exercise? __~_~_
Do you have a family history of elevated blood cholesterol or he:lrt disease?
Yes No _
IF YES, \Vhich family member?


















I. Have you had a cold in the l:lst month?
IF YES. when?
how long did it last?
did you ha ve a fever?
Ha.ve you h:1d the flu in the last month?
IF YES. when
how long did it last?





3. Have you had any other illness last month? Yes
IF YES. what type of illness?
how long did it last?
did you have :1 fever?
No
4. IF YES TO ANY OF QUESTIONS 1 - 3, did you continue to take your
supplement during the illness? Yes No
5. Did your exercise pattern change last month? Yes No
IF YES TO QUESTION 5. what way did your exercise pattern
change: _
Type of exercise? _
IF YES. how often did you exercise? _
IF YES. how long do you presently e:-<crcise? _
APPENDIX G
PROCEDURES FOR BIOELECTRICAL IMPEDANCE
AND KNEE HEIGHT COLLECTIONS
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Bioelectrical impedance procedure:
1) Height and weight were measured immediately before this procedure.
This infonnation along with age and gender were programmed into the bioelectrical
impedance analyzer.
2) Fasted subjects lay in a supine position on a large heavy wooden table
with the right arm and the portion of the right leg below the knee exposed. All
jewelry was removed. Hands were placed six inches from the sides and feet were
placed six inches apart.
3) Four sensor electrodes were placed on the right foot, ankle, wrist and
hand. The right foot was relaxed and the first electrode was placed on the top center
of the foot near the base of the toes. The same foot was dorsiflexed (flexed toward
the head) and the second electrode was placed on the top of the relaxed ankle against
the edge where the crease had formed. The right wrist was dorsiflexed and the third
electrode was placed on the top of the relaxed wrist against the edge where the
crease had formed. The hand was relaxed and the fourth electrode was placed on
the center top of the hand near the edge of the first and second knuckles towards the
thumb.
4) Red (positive) sensor cables were attached to electrodes on the wrist and
ankle and black (negative) sensor cables were attached to electrodes on the hand and
foot. The cables were connected to the bioelectrical impedance unit.
5) The subject was reminded to relax and remain motionless for the ten
second test. Duplicate test results were printed out on a body composition test
summary sheet. Infonnation obtained included percent body fat, body fat weight,
lean body weight, basal metabolic rate, total body water and bioresistance.
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Knee height procedure:
1) Subjects lay in a supine position on a heavy wooden table with the left
knee and left ankle bent at a 90 degree angle. Angles of the knee and foot were
positioned with a triangle provided by Ross Labs. The knee caliper was placed with
the fixed blade under the heel in line with the tibia (large bone in the lower leg) and
over the lateral malleolus (ankle bone). The sliding blade was brought down against
the thigh about two inches behind the patella (kneecap).
2) The measurement was held with a locking mechanism on the caliper and
read to the nearest 0.1 cm through a viewing window.
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APPENDIX H
KNEE HEIGHT MEASUREMENT DIAGRAM
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3. To hold the meuurem~n(.push
(he lo,-'klnll le\'tr 3way Irom th~
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Stature for 3dult, 60 to 90 woars old
can ~ ~umat~ from kn~ h~llZht
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Source: .#50452, Ross Labs, Columbus, Ohio, 1989.
APPENDIX I
PROCEDURE FOR BLOOD COLLECTION
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Blood collection procedure:
1. Site selection: A prominent vein was selected at the antecubital area of
the non dominant arm. If there was no prominent vein in that area, a vein at the
dorsum of the hand was used.
2. Site preparation: A tourniquet was placed approximately two inches
above the antecubital area. An alcohol swab was used to clean the antecubital area.
3. Skin puncture: A 21 gauge butterfly needle was attached to the first
plasma tube and used to puncture the antecubital vein. A piece of micropore tape
was placed over the butterfly needle to stabilize it.
4. Specimen collection: After releasing the tourniquet, blood was allowed to
flow into the tube by slowly pulling on the plunger. Ten milliliters of blood was
collected in the first plasma tube. One hundred microliters of sodium citrate
(trisodium citrate 300 giL) was used as an anticoagulant. The end of the butterfly
needle tube near the plasma tube was kinked to remove the first plasma tube and
attach the second plasma tube. After 10 ml of blood was collected in the second
plasma tube, the butterfly needle tube was kinked while the second plasma tube was
removed and the serum tube was attached to collect ten milliliters of blood. The
first anticoagulant tube was centrifuged at 2500 rpm for 30 minutes immediately
after blood collection and the serum tubes were allowed to clot on ice for two hours.
5. Puncture treatment: After the blood samples were collected, a sterile
cotton ball was applied to the puncture site with a slight pressure until the bleeding
stopped. A bandage was then placed over the puncture wound.
6. Biohazard disposal: All butterfly needles were discarded into a biohazard
container for sharps and all used cotton balls were discarded into a biohazard bag.
7. Immediately following the blood draw, subjects received orange juice and
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Modifications to glucose determination:
Plasma glucose was determined using Sigma Diagnostics procedure No. 510, 5t
Loius, MO. Modifications to the procedure were made by decreasing sample
amounts by three-fifths to minimize waste. To blank, standard, and test tubes, 200
ul of water was added. Ten ul of water, standard and sample was added to blank,
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